|
Apr 1
|
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health
|
|
Feb 21
|
IGC Pharma expands Holiby line with ‘Longevity’, ‘Renew’
|
|
Feb 20
|
IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market
|
|
Feb 18
|
IGC Pharma Reports Third Quarter Fiscal 2025 Results
|
|
Feb 11
|
IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)
|
|
Oct 17
|
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
|
|
Aug 26
|
IGC Announces Results of its 2024 Annual Stockholders Meeting
|
|
Jun 25
|
IGC Pharma's TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
|
|
Jun 24
|
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
|
|
Jun 18
|
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
|
|
Apr 16
|
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
|
|
Apr 9
|
IGC Pharma Adds Advisor in Artificial Intelligence
|
|
Mar 26
|
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
|
|
Mar 20
|
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
|
|
Mar 20
|
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
|
|
Mar 12
|
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
|
|
Feb 28
|
Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model
|
|
Feb 1
|
IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model
|
|
Dec 19
|
Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s
|
|
Dec 6
|
IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials
|